Rajeev Shah Net Worth

The estimated Net Worth of Rajeev M. Shah is at least $65.6 Million dollars as of 13 March 2020. Mr. Shah owns over 6,337,135 units of Kala Bio stock worth over $65,465,170 and over the last 8 years he sold KALA stock worth over $0. In addition, he makes $134,972 as Independent Director at Kala Bio.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Shah KALA stock SEC Form 4 insiders trading

Rajeev has made over 11 trades of the Kala Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 6,337,135 units of KALA stock worth $49,999,995 on 13 March 2020.

The largest trade he's ever made was buying 6,337,135 units of Kala Bio stock on 13 March 2020 worth over $49,999,995. On average, Rajeev trades about 433,449 units every 29 days since 2016. As of 13 March 2020 he still owns at least 10,874,613 units of Kala Bio stock.

You can see the complete history of Mr. Shah stock trades at the bottom of the page.

Rajeev Shah biography

Rajeev M. Shah serves as Independent Director of the Company. Mr. Shah has has served as a member of our board of directors since July 2015. Since 2004, Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics and current 5% beneficial stockholder. Mr. Shah is currently a member of the board of directors of Solid Biosciences, Inc., Eidos Therapeutics, Inc., Satsuma Pharmaceuticals, Inc., and Black Diamond Therapeutics, Inc., all publicly-traded biopharmaceuticals companies. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from June 2015 through April 2018 and Ra Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from July 2015 through April 2020. Mr. Shah holds a B.A. in Chemistry from Cornell University.

What is the salary of Rajeev Shah?

As the Independent Director of Kala Bio, the total compensation of Rajeev Shah at Kala Bio is $134,972. There are 9 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.

How old is Rajeev Shah?

Rajeev Shah is 43, he's been the Independent Director of Kala Bio since 2015. There are 17 older and no younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.

Insiders trading at Kala Bio

Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.

What does Kala Bio do?

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Complete history of Mr. Shah stock trades at KalVista Pharmaceuticals Inc, Kala Bio, Solid Biosciences Inc, Eidos Therapeutics Inc, Black Diamond Therapeutics Inc, and Satsuma Pharmaceuticals

Kala Bio executives and stock owners

Kala Bio executives and other stock owners filed with the SEC include:

• Mark Iwicki,
  Chairman of the Board, President, Chief Executive Officer
• Todd Bazemore,
  Chief Operating Officer
• Eric Trachtenberg,
  Chief Compliance Officer, General Counsel, Secretary
• Kim Brazzell,
  Chief Medical Officer
• Mark T. Iwicki,
  Chairman & CEO
• Dr. Kim Brazzell Ph.D.,
  Head of R&D and Chief Medical Officer
• Hongming Chen,
  Chief Scientific Officer
• Todd Bazemore,
  Pres & COO
• Andrew Koven,
  Lead Independent Director
• Rajeev Shah,
  Independent Director
• Gregory Perry,
  Independent Director
• Robert Paull,
  Independent Director
• Howard Rosen,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• Mary Reumuth,
  Chief Financial Officer, Treasurer
• James Patnoe,
  Sr. VP of Market Access, Commercial Operations & Pricing
• Vincent Kosewski,
  Sr. VP of Manufacturing & Supply Chain Management
• Michele LaRussa,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Kathleen McCann Kline,
  Sr. VP of Marketing
• Eric L. Trachtenberg,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Jill S. Steier,
  Exec. Director of Investor Relations & Corp. Communications
• Mary Reumuth CPA, CPA,
  CFO & Treasurer
• Dr. Justin Hanes Ph.D.,
  Founder & Chair of the Scientific Advisory Board
• Capital Partners Ii, Llcenr...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Associates, L.L.C.Caxton Co...,
  
• Paulina Hill,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Robert I Tepper,
  Director
• Robert Langer,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Michele La Russa,
  Sr. VP, Regulatory and Quality
• C. Daniel Myers,
  
• Marjan Farid,
  
• Capital Management, L.P.Ra ...,
  
• Romulus K Brazzell,
  SEE REMARKS
• Mark S. Blumenkranz,
  
• Darius Kharabi,
  CHIEF BUSINESS OFFICER